PriceTargets.com logo

CNS Pharmaceuticals - CNSP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.50
  • Forecasted Upside: 311.52%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.12 As of 10/30/2024 05:27 PM ET
▼ -0.0162 (-11.76%)

This chart shows the closing price for CNSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CNS Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNSP

Analyst Price Target is $0.50
▲ +311.52% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CNS Pharmaceuticals in the last 3 months. The average price target is $0.50, with a high forecast of $0.50 and a low forecast of $0.50. The average price target represents a 311.52% upside from the last price of $0.12.

This chart shows the closing price for CNSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in CNS Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/10/2024Maxim GroupUpgradeHold ➝ Buy$0.50
8/17/2022Maxim GroupDowngradeBuy ➝ Hold
5/26/2022Maxim GroupLower Target$1,500.00
8/27/2021Alliance Global PartnersInitiated CoverageBuy$6,000.00
2/2/2021Brookline Capital ManagementInitiated CoverageBuy$15,000.00
12/28/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
8/24/2020LADENBURG THALM/SH SHInitiated CoverageBuy$16,500.00
12/4/2019BenchmarkInitiated CoverageSpeculative Buy
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
CNS Pharmaceuticals logo
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Read More

Today's Range

Now: $0.12
Low: $0.12
High: $0.14

50 Day Range

MA: $0.14
Low: $0.11
High: $0.20

52 Week Range

Now: $0.12
Low: $0.10
High: $137.50

Volume

7,890,399 shs

Average Volume

5,304,179 shs

Market Capitalization

$4.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of CNS Pharmaceuticals?

The following sell-side analysts have issued stock ratings on CNS Pharmaceuticals in the last twelve months: Maxim Group.
View the latest analyst ratings for CNSP.

What is the current price target for CNS Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for CNS Pharmaceuticals in the last year. Their average twelve-month price target is $0.50, suggesting a possible upside of 311.5%. Maxim Group has the highest price target set, predicting CNSP will reach $0.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $0.50 for CNS Pharmaceuticals in the next year.
View the latest price targets for CNSP.

What is the current consensus analyst rating for CNS Pharmaceuticals?

CNS Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNSP will outperform the market and that investors should add to their positions of CNS Pharmaceuticals.
View the latest ratings for CNSP.

What other companies compete with CNS Pharmaceuticals?

Other companies that are similar to CNS Pharmaceuticals include Adamis Pharmaceuticals, Pulmatrix, Cumberland Pharmaceuticals, TherapeuticsMD and Minerva Neurosciences. Learn More about companies similar to CNS Pharmaceuticals.

How do I contact CNS Pharmaceuticals' investor relations team?

CNS Pharmaceuticals' physical mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The company's listed phone number is 800-946-9185 and its investor relations email address is [email protected]. The official website for CNS Pharmaceuticals is www.cnspharma.com. Learn More about contacing CNS Pharmaceuticals investor relations.